Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage reported in Row 11 is calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934 (as amended, the "Exchange Act") and based on an aggregate total of 23,328,390 shares of the common stock of Lyell Pharmaceuticals, Inc. (the "Issuer") outstanding as of March 31, 2026, as reported by the Issuer in its preliminary prospectus (the "Prospectus") (File No. 333-294884) dated April 3, 2026, incorporated in the Issuer's Form S-3 registration statement filed with the Securities and Exchange Commission (the "SEC") on April 3, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  For purposes of Rule 13d-3 under the Exchange Act, all shares of the Issuer's common stock held by Explore may be deemed to be beneficially owned by Jeffrey P. Bezos as the sole member of Explore. The percentage reported in Row 11 is calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act and based on an aggregate total of 23,328,390 shares of the Issuer's common stock outstanding as of March 31, 2026, as reported by the Issuer in the Prospectus.


SCHEDULE 13G



 
Explore Investments LLC
 
Signature:/s/ Paul Dauber
Name/Title:Paul Dauber/its Manager
Date:05/08/2026
 
Jeffrey P. Bezos
 
Signature:/s/ Jeffrey P. Bezos
Name/Title:Jeffrey P. Bezos/an Individual
Date:05/08/2026